The healthcare M&A market is entering a new era—defined by disciplined diligence, creative deal structures, and emerging categories such as wellness, longevity, and aesthetics. In the latest episode of The Dealmaker’s Series, I sat down with James Turcott, Partner at Skytale Group, to discuss the current state of deal flow, evolving trends in the lower middle market, and how AI and regulation are shaping the future of healthcare transactions.
Skytale Group is a management consulting and investment banking firm built specifically to bring sophistication to the lower middle market. With deep expertise in healthcare—especially in medical aesthetics and dental practices—the firm helps founder-led businesses transition to strategic partners and private equity groups. As Turcott put it, “Our clients typically range from $1 million to $15 million in EBITDA, and we focus on aligning founder-owners with investors who understand the unique dynamics of provider-led organizations.”
See full interview here
The State of Healthcare Deal Flow in 2025
Over the past six months, deal flow in healthcare has shifted gears. Turcott noted that activity slowed temporarily during the election period as investors watched for signs of regulatory change, but the market has since rebounded. “We’ve seen a real uptick,” he explained. “Deals that were paused or delayed in 2024 are now back on the table. Heading into Q1 of next year, we expect a strong wave of closings as buyers re-engage with renewed confidence.”
For firms like Skytale, that momentum is particularly strong in medical aesthetics and dental services—two verticals that private equity continues to view as scalable, repeatable, and consumer-resilient. What’s especially interesting, Turcott added, is how sub-sectors like wellness and longevity have spun out from traditional MedSpa models.
“We’re seeing new demand for hormone replacement therapy, concierge medicine, and men’s health practices—businesses that sit at the intersection of healthcare and lifestyle.”
This hybridization of healthcare—where medicine meets consumer experience—is fueling fresh deal activity. Practices that once operated independently are now becoming part of integrated wellness platforms with strong brand identities, patient data strategies, and operational synergies attractive to investors.
Evolving Deal Structures in a Provider-Dependent Market
In the current healthcare M&A climate, deal creativity has become a competitive advantage. “Most of our transactions are structured with a rollover equity component,” said Turcott. “It’s typically around 70% cash at close and 30% equity rollover. Buyers want to ensure that providers remain aligned with the long-term growth of the platform.”
That alignment has become essential in an industry where provider relationships drive enterprise value. Unlike pure asset-based acquisitions, healthcare deals rely heavily on human capital—the physicians, nurses, and clinical teams who sustain recurring revenue and patient trust.
Interestingly, some buyers are pushing for higher rollover percentages, often exceeding 25%. “It’s less about the percentage itself and more about shared vision,” Turcott explained. “When the seller stays engaged and has skin in the game, the platform typically grows faster post-acquisition.”
This approach mirrors a larger trend across the lower middle market: a focus on partnership-driven exits rather than full cash buyouts. As interest rates and capital costs remain tight, creative structures—earnouts, minority stakes, and staged exits—are becoming increasingly common.
Due Diligence Takes Longer—but Builds Stronger Deals
Across industries, deal professionals are seeing a slower, more methodical diligence process—and healthcare is no exception. Turcott shared that timelines have expanded from 60–90 days to as long as 120. “Buyers are being more cautious,” he said.
“It’s not that they’re less confident in the market—it’s that lenders, regulators, and investors are demanding more documentation, more verification, and more clarity before deals cross the finish line.”
While the extra time can frustrate founders eager to close, it also means higher-quality transactions with fewer post-close surprises. Skytale’s role as both a consulting and investment banking partner gives it a unique vantage point in managing client expectations and ensuring that diligence leads to stronger valuation outcomes.
This diligence discipline reflects a more mature phase of the M&A cycle—one where operational rigor, transparency, and compliance have become differentiators, not afterthoughts.
Why Texas and DFW Remain a Magnet for Healthcare Deals
When asked about regional dynamics, Turcott pointed to Texas—and particularly Dallas–Fort Worth—as a consistent bright spot. “Texas has one of the most business-friendly regulatory environments in the country,” he said. “We’ve completed several transactions here, and the environment is highly conducive to dealmaking.”
From a macro perspective, Texas’ combination of favorable tax policies, population growth, and healthcare infrastructure expansion continues to attract capital. “DFW in particular offers access to both clinical talent and investment networks,” Turcott added. “It’s a region where healthcare entrepreneurs and private equity firms alike can thrive.”
For firms playing in the lower middle market, this regional advantage translates into deal velocity and post-close growth potential—two critical factors for buyers navigating a competitive investment landscape.
Regulation and AI: The Twin Forces Shaping Healthcare’s Future
While Texas offers a supportive environment, not every state makes it easy to scale healthcare businesses. “We’re keeping an eye on regulatory developments,” Turcott explained, referencing a proposed Texas bill that would have required a medical doctor to be present in MedSpas full-time. “That kind of regulation would’ve crippled the business model, so understanding the legislative landscape is essential for investors.”
Regulatory clarity—or lack thereof—remains one of the biggest determinants of deal feasibility in healthcare. As new states tighten compliance requirements, only buyers with deep operational expertise will be able to navigate the complexity successfully.
At the same time, artificial intelligence is reshaping the healthcare operating model. “You can’t go to a conference without hearing about AI,” said Turcott. “We’re seeing it used for patient acquisition, retention, appointment management, and analytics. It’s still early, but the operators who learn to use AI well will separate themselves quickly.”
AI’s role in healthcare M&A is twofold: it enhances operational efficiency for existing platforms, and it increases the attractiveness of AI-integrated businesses to buyers. Whether it’s predictive patient analytics, digital marketing optimization, or workflow automation, AI is rapidly becoming part of the due diligence checklist for investors.
Looking Ahead: Steady Optimism in the Lower Middle Market
As 2025 moves into its final quarter, optimism in the healthcare M&A sector feels measured—but real. Interest rate cuts, regulatory clarity, and the maturation of niche markets like aesthetics and wellness have set the stage for a strong 2026.
“Overall, we expect a continuation of what we’re seeing now,” Turcott concluded. “If rates come down a bit more, and if regulation remains stable, healthcare will continue to be one of the most active lower-middle-market sectors in the country.”
For founder-led healthcare practices, that translates to one clear message: prepare early. Buyers are active, capital is returning, and strategic positioning now can make the difference between a good exit and a great one.
Leave a Reply